Banking and RBI
RBI issues final Directions on Minimum Capital Requirements for Market Risk under Basel III
21 September 2026 | Reserve Bank of India
The RBI issued the Reserve Bank of India (Commercial Banks - Minimum Capital Requirements for Market Risk) Directions, 2026 on 21 September 2026. The draft guidelines had been issued on 17 February 2023, proposing the Simplified Standardised Approach (SSA) for computing market risk capital under the revised Basel III framework.
The RBI said feedback on the draft was examined and modifications were incorporated in the final Directions, which aim to align market risk guidelines with the revised Basel III framework while ensuring simplicity of regulations.
Key facts- Issued: 21 September 2026
- Draft guidelines: 17 February 2023
- Approach: Simplified Standardised Approach (SSA)
- Applies to: commercial banks
Exam takeaway: Market risk capital is the capital banks hold against losses from market price movements.
Quick revision: RBI market risk Directions (21 September 2026).
Reserve Bank of India original sourceBanking and RBI
RBI overnight VRRR auction of 21 September 2026: result
21 September 2026 | Reserve Bank of India
The RBI's result for the Overnight Variable Rate Reverse Repo (VRRR) auction held on 21 September 2026 showed a notified amount of Rs 1,00,000 crore, offers of Rs 75,058 crore and the same amount accepted.
Both the cut-off rate and the weighted average rate were 5.24 per cent for the 1-day tenor.
Key facts- Auction date: 21 September 2026
- Notified amount: Rs 1,00,000 crore
- Accepted: Rs 75,058 crore
- Cut-off rate: 5.24 per cent
Exam takeaway: A VRRR auction absorbs surplus liquidity from the banking system.
Quick revision: RBI VRRR result (21 September 2026).
Reserve Bank of India original sourceGovernment Schemes
7th National Formulary of India launched; Biovigilance Programme announced
21 September 2026 | Press Information Bureau
PIB said Union MoS for Health Anupriya Patel launched the 7th Edition of the National Formulary of India (NFI) on 21 September 2026 at the Indian Pharmacopoeia Commission's 6th National Pharmacovigilance Week programme in New Delhi, and announced the Biovigilance Programme of India, approved by the Government, under which the IPC will lead monitoring of adverse events linked to organ and tissue transplantation.
PIB said India rose from 123rd position to 8th globally in contributions to the WHO patient safety database, and around 1,150 ADR Reporting Centres are operational. The Pharmacovigilance Week runs from 17 to 23 September 2026.
Key facts- Launched: 7th National Formulary of India
- Biovigilance monitoring led by: IPC
- India's rank in WHO database contributions: 8th
- ADR Reporting Centres: around 1,150
Exam takeaway: IPC is the Indian Pharmacopoeia Commission.
Quick revision: National Formulary of India (PIB, 21 September 2026).
Press Information Bureau original source